oral glp-1 weight loss FDA approves Foundayo, an alternative to Wegovy and Ozempic Oral GLP-1 Market to Rise

According to FAIR Healths 2025 analysis of more than 51 billion commercial insurance claims, the share of adults prescribed a GLP-1 medication increased from 0.9% in 2019 to 4% in 2024

FDAs concerns with unapproved GLP-1 drugs used for weight loss (2025)

Despite these promising developments, GLP-1 therapies remain relatively new

When individuals fail to achieve their desired weight loss or appearance goal in the short term, they often abandon behavior change altogether, suggesting that using appearance as the primary driver for health behavior change might be an ineffective strategy [24]

We thank C

Our rankings are based on medical standards and patient care quality